Related Experiment Videos
Chimeric herpes simplex virus/adeno-associated virus amplicon vectors.
Daniel L Glauser1, Mathias Ackermann, Okay Saydam
1Institute of Virology, University of Zurich, Switzerland.
Current Gene Therapy
|June 22, 2006
Summary
Hybrid herpes simplex virus type 1/adeno-associated virus (HSV/AAV) vectors offer large transgene capacity and stable expression. Understanding their replication origins may improve integration efficiency for gene therapy applications.
Area of Science:
- * Gene Therapy
- * Virology
- * Molecular Biology
Background:
- * Chimeric HSV/AAV amplicon vectors combine large transgene capacity of HSV-1 with AAV's site-specific integration potential.
- * These hybrid vectors demonstrate prolonged transgene expression compared to standard HSV-1 amplicons.
- * HSV/AAV vectors can achieve high-rate integration at the AAVS1 site on human chromosome 19, though random integration also occurs.
Purpose of the Study:
- * To investigate the DNA replication origins active during HSV/AAV hybrid amplicon packaging.
- * To understand the interactions between HSV-1 and AAV replication origins.
- * To identify strategies for improving hybrid vector design for efficient and precise large transgene integration.
Main Methods:
- * Analysis of DNA replication origins including HSV-1 ori, AAV inverted terminal repeats (ITRs), and p5 promoter/ori.
- * Examination of viral replication factors and AAV Rep protein during hybrid amplicon packaging into HSV-1 virions.
Main Results:
- * At least three viral origins of DNA replication are active during HSV/AAV hybrid amplicon packaging.
- * The interplay between HSV-1 replication factors and AAV Rep protein influences vector replication and packaging.
Conclusions:
- * A detailed understanding of these replication origins and their interactions is crucial.
- * This knowledge can facilitate the design of novel HSV/AAV hybrid vectors for efficient and precise large transgene integration into the human genome.